Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemDiv, a contract research organization, and Avineuro Pharmaceuticals, a developer of novel small molecules for neurology and psychiatry, have extended the term of their R&D collaboration including formulation, safety and early clinical development studies in areas of neurodegenerative and psychiatric disorders.
Subscribe to our email newsletter
R&D services will be provided by Chemical Diversity Research Institute, ChemDiv’s research subsidiary based in Moscow. The new agreement provides for research funding of clinical candidate compounds to POC.
Avineuro is responsible for further clinical development and commercialization of drug candidates AVN101, AVN211, and additional compounds that may be nominated for development from the ongoing research and discovery under the agreement.
ChemDiv has previously entered into an out-licensing and collaboration agreement with Avineuro to develop multiple compounds for Alzheimer disease and schizophrenia.